DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for multiple epiphyseal dysplasia type 5 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMultiple epiphyseal dysplasia type 5 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for multiple epiphyseal dysplasia type 5 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No drug treatment is mentioned in any of the three abstracts. The 2010 report describes a single 9-year-old Korean girl with autosomal recessive multiple epiphyseal dysplasia caused by novel compound heterozygous mutations in the DTDST (SLC26A2) gene. This is the first Korean case attributed to that gene, and the authors state it expands the known disease spectrum, but no therapeutic intervention was tested or proposed.
The 1984 abstract describes a 4-year-old female with multiple epiphyseal dysplasia who presented with severe slipping of the capital femoral epiphysis. No drug or treatment is discussed. The 1973 report covers three cases of dysplasia epiphysealis hemimelica (a different condition from multiple epiphyseal dysplasia type 5) and stresses that treatment must be individualised depending on deformity and pain, but again no drug is named.
There is no evidence from these abstracts for any drug that alters the course of multiple epiphyseal dysplasia type 5. What is missing is any clinical trial, any tested compound, any animal model of drug treatment for this specific genotype, and any systematic patient stratification by mutation type. No funding source for a drug-repurposing study is mentioned.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Korean Medical Science · 2010 · 17 citations · open access
Autosomal Recessive Multiple Epiphyseal Dysplasia in a Korean Girl Caused by Novel Compound Heterozygous Mutations in the DTDST (SLC26A2) Gene
AbstractMultiple epiphyseal dysplasia is caused by heterogeneous genotypes involving more than six genes. Recessive mutations in the DTDST gene cause a phenotype of recessive multiple epiphyseal dysplasia (rMED). The authors report a 9-yr old Korean girl with the rMED phenotype having novel compound heterozygous mutations in the DTDST gene, which were inherited from both parents. This is the first Korean rMED case attributed to DTDST mutations, and expands the spectrum of diseases caused by DTDST mutations.
AbstractMultiple epiphyseal dysplasia, first described by Fairbank (1947), is characterised by dwarfism, stubby digits and mottling or irregularity in density and outline of the developing epiphyses on the roentgenograms. We report a 4-year-old female case of multiple epiphyseal dysplasia showing severe slipping of the capital femoral epiphysis.
Dysplasia Epiphysealis Hemimelica; Report of Three Cases
Abstract1. Three cases of dysplasia epiphysealis hemimelica are reported and the literature is briefly reviewed.2. The course of these cases is described and discussed.3. It is stressed that the treatment of this disease must be individualized depending on the amount of deformity and pain.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
